FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer

Orphan Drug Designation: What is it and why is it a big deal for biotech stocks?

While most small cap health stocks dream of commercialisation, healthcare companies at an early stage get excited about achieving Orphan Drug Designation. Achieving this won’t be as meaningful to the bottom line as a stock receiving regulatory approval, but it is a big step nonetheless. If and when commercialisation is achieved, this will have been…

FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer

The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.

FDA Grants Orphan Drug Designation to Liposomal Gemcitabine in Biliary Tract Cancer

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive malignancy.